Slc7a9 knockout mouse is a good cystinuria model for antilithiasic pharmacological studies

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Cystinuria is a hereditary kidney disorder causing recurrent kidney stones due to defective cystine and amino acid transport.
• Mutations in SLC3A1 and SLC7A9 genes lead to Type A and B cystinuria, respectively.
• Current treatments focus on preventing stone formation and using thiols like d-penicillamine (DP) for cystine dissolution.

Purpose of the Study:

• To validate a Slc7a9 knockout mouse model for studying cystinuria drug efficacy.
• To establish a noninvasive method for quantifying cystine calculi mass using X-ray densitometry.
• To assess the therapeutic effects of d-penicillamine (DP) on cystine lithiasis in the validated mouse model.

Main Methods:

• A 5-week d-penicillamine (DP) treatment protocol was applied to lithiasic Slc7a9 knockout mice.
• Kidney stone burden was quantified noninvasively using X-ray densitometry before and after treatment.
• Urinary amino acid levels were measured in DP-treated and untreated mice.

Main Results:

• DP-treated mice showed significant reductions in calculi size compared to untreated controls.
• Urinary cystine excretion was significantly altered in DP-treated mice.
• Histopathological analysis revealed less severe urinary system damage in DP-treated mice.

Conclusions:

• The Slc7a9 knockout mouse model is validated for studying cystine lithiasis.
• This model effectively demonstrates the therapeutic potential of DP in reducing cystine stones and kidney damage.
• The validated model provides a platform for testing novel therapeutic agents for cystinuria.